SentienBiotech

@SentienBiotech

Sentien Biotechnologies, Inc. is a privately owned, clinical-stage company developing novel approaches to cell therapy.

Vrijeme pridruživanja: travanj 2017.

Tweetovi

Blokirali ste korisnika/cu @SentienBiotech

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @SentienBiotech

  1. 22. sij

    is Leaders World & World Stem Cell Summit in Miami! Sentien VP of Operations, Dr. , will be speaking about Sentien's ex vivo allogeneic MSC therapy on Jan 23 at 1:50pm!

    Poništi
  2. proslijedio/la je Tweet
    13. pro 2019.

    The meeting ends on a high note, with a very exciting report on the promising Sentien clinical trial for kidney damage by Biju Parekkadan, PhD, Rutgers University and Office of CEO, Sentien Biotechnologies, Inc.

    Poništi
  3. 12. pro 2019.

    is at the Cellular Therapeutics in Trauma and Critical Care conference in San Diego! Cofounder Dr. Biju Parekkadan will speak on 12/13 at 4:05pm & Sentien has a booth in the Exhibit Hall. Stop by and meet CEO Brian Miller and Dr. Parekkadan!

    Poništi
  4. proslijedio/la je Tweet
    7. lis 2019.

    2019 TERMIS-AM conference - Unique insight into translational challenges in TERMIS from leaders in industry and academia! Opening Symposium panel discussion with CEOs, VP consultants, and professors. Early bird registration end Nov 4th!

    Poništi
  5. proslijedio/la je Tweet

    Chris Gemmiti, VP of Operations discusses the highs and lows of mesenchymal and whether their peak is yet to come. Read more:

    Poništi
  6. 7. stu 2019.

    cofounder Dr. Biju Parekkadan to speak tomorrow, 11/8, at UMass Amherst's BTP Symposium on Cell-Based Therapies!

    Poništi
  7. proslijedio/la je Tweet

    Chris Gemmiti, VP of Operations gave his take on the future of Mesenchymal and top 3 triumphs in cell and gene therapies to date.

    Poništi
  8. 1. stu 2019.

    Check out the finished products from 's Halloween pumpkin carving contest! Congrats to our winners! 🎃

    Poništi
  9. 23. lis 2019.

    CEO Brian Miller to present today at BIO Investor Forum in San Fran at 10:45am in Elizabethan A!

    Poništi
  10. 21. lis 2019.

    Check out CEO Brian Miller's presentation from the 2019 Cell & Gene Meeting on the Mesa!

    Poništi
  11. 3. lis 2019.

    Here's CEO Brian Miller discussing Sentien's ex vivo cell therapy applications yesterday Cell & Gene Therapy Meeting on the Mesa!

    Poništi
  12. 1. lis 2019.

    is at the Cell & Gene Meeting on the Mesa in Carlsbad, CA! CEO Brian Miller will present on Wed Oct 2 at 4pm in the Cognate Bioservices Ballroom.

    Poništi
  13. 13. ruj 2019.

    is NA 2019 Regional Meeting in Madison, WI! Attend Exec Director of R&D Dr. Rita Barcia's talk about Sentien's MSC therapy for subjects with AKI on Saturday, 9/14 from 10:45am-12:15pm in Ballroom B and check out our poster, too!

    Poništi
  14. 12. ruj 2019.

    Exec Director of R&D, Dr. Rita Barcia, speaking on a panel about Next Gen Therapies!

    Poništi
  15. 10. ruj 2019.
    Poništi
  16. 9. ruj 2019.

    Hear from executives Dr. and Dr. Rita Barcia this week @Bioprocess365 Cell & Gene Therapy Bioprocessing & Commercialization conference in Boston!

    Poništi
  17. proslijedio/la je Tweet
    21. svi 2019.

    Great perspectives from on the engineering of effective cell therapeutics. .

    Poništi
  18. 20. svi 2019.

    Check out 's article, Convergence of Cell Pharmacology and Drug Delivery, just published in Stem Cells Translational Medicine!

    Poništi
  19. 20. svi 2019.

    Check out the feature on cofounder Dr. Biju Parekkadan's graphic novel!

    Poništi
  20. 29. tra 2019.

    cofounder Dr. Biju Parekkadan is speaking at , today from 11:45am-12pm! He will be discussing Reprogramming Human Immune Responses Using Ex Vivo MSC Bioreactor Therapy.

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·